{"id":"port-sites-infiltration-bupivacaine0-25","brandName":"Port-sites infiltration:Bupivacaine0.25%","genericName":"Port-sites infiltration:Bupivacaine0.25%","companyId":"hospital-general-universitario-elche","companyName":"Hospital General Universitario Elche","phase":"phase_3","status":"active","modality":"Small molecule","aliases":["Port-sites infiltration with bupivacaine"],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"Bupivacaine 0.25% port-sites infiltration is used for postoperative analgesia in laparoscopic sleeve gastrectomy. It has completed a Phase 3 trial and shows promise in reducing pain without significant safety concerns.","enrichmentLevel":3,"visitCount":0,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Bupivacaine acts as a local anesthetic by inhibiting the influx of sodium ions through voltage-gated sodium channels, which are essential for the initiation and propagation of nerve impulses. This blockade of sodium channels prevents the depolarization of nerve fibers, resulting in a loss of sensation and pain relief.","oneSentence":"Bupivacaine blocks sodium channels in nerve fibers, preventing depolarization and relieving pain.","_ai_confidence":"high"},"administration":{},"safety":{"commonSideEffects":[{"rate":"null","effect":"Central nervous system toxicity"},{"rate":"null","effect":"Cardiovascular toxicity"},{"rate":"null","effect":"Nausea and vomiting"}]},"trials":[],"indications":{"approved":[{"name":"Postoperative pain management"},{"name":"Regional anesthesia"}]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}